Massachusetts Beats National Average in Breast Cancer Mortality

When the CDC released its latest mortality figures in the middle of Breast Cancer Awareness Month, the numbers for Massachusetts caught a few eyebrows. In 2024 the Bay State saw 783 women lose their battle with breast cancer, which translates to an age‑adjusted death rate of 15.2 per 100,000. That’s a comfortable gap from the national average of 18.7, and even a touch better than the low‑end state of Rhode Island (14.4).

But don’t let the lower death rate give the false impression that everything’s fine. While deaths have been edging down for a few decades—thanks to earlier detection and more effective treatments—the sheer number of women diagnosed each year is on the rise. The American Cancer Society, cited by Breastcancer.org, notes an annual 1 % increase in incidence from 2012 through 2021, with especially noticeable jumps among women under 50 and among Hispanic and Asian‑American Pacific Islander groups.

Nationwide, 43,402 women died of breast cancer in 2024, a modest uptick from the previous three years. Yet the age‑adjusted mortality rate still fell from 19.4 in 2021 to 18.7 today. That dip matters because raw death counts can be skewed by population growth and aging, while age‑adjusted rates give a truer picture of risk.

Geography plays a surprisingly big role, too. The Southeast and Appalachia—think Alabama, Georgia, Mississippi, South Carolina, Tennessee, and West Virginia—posted rates well above the national average. Meanwhile, New England, the northern Plains and parts of the Upper Midwest tended to sit below it. There were outliers, of course: Oklahoma, New Mexico, Nevada and Idaho saw higher numbers, while Florida actually fell under the national benchmark.

Why these patterns exist isn’t fully spelled out in the CDC report. Access to timely screening, prompt diagnosis and swift treatment are all likely contributors, but the data alone can’t prove cause‑and‑effect. What’s clear is that early detection saves lives. The CDC echoes the U.S. Preventive Services Task Force in recommending a mammogram every two years for women aged 40‑74 who are at average risk. For those with a family history or a known genetic mutation, doctors may suggest starting sooner or adding other tests.

And the numbers back up the importance of those guidelines: more than 99 % of women whose cancer is caught while still confined to the breast survive at least five years. Still, mammograms aren’t perfect—they can miss a tumor or flag something that turns out harmless. That’s why a conversation with your health‑care provider about personal risk factors is essential.

Insurance coverage for screening is now the norm; most plans must cover a mammogram every one to two years starting at age 40 without a co‑pay. If you’re uninsured or underinsured, the CDC’s National Breast and Cervical Cancer Early Detection Program may offer free or low‑cost scans, and the FDA maintains a searchable list of certified facilities.

Looking ahead, experts project about 321,910 invasive breast‑cancer diagnoses in 2026, plus roughly 60,730 cases of ductal carcinoma in situ, a non‑invasive form. Roughly one in eight American women will develop invasive breast cancer sometime in their lives.

One lingering disparity is race. Black women, while less likely to be diagnosed, face a markedly higher risk of death compared with white women—a gap that persists even as overall mortality falls.

All told, Massachusetts is doing better than many states when it comes to mortality, but the rising tide of new diagnoses reminds us that vigilance, equitable access to care, and continued research remain vital.